Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Yu Takahashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3066-023X; OpenAlex author ID A5032295043, A5122389710. Sources: OpenAlex.

Their work

Papers
50 (first author 1, last author 24)
Trials
0
Grants
0
Labs led
1
Collaborators
101
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 5 papers · 2021: 3 papers · 2022: 13 papers · 2023: 11 papers · 2024: 4 papers · 2025: 6 papers · 2026: 5 papers

Papers 50

  1. Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1002/jhbp.70058↗
  2. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  3. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Last author DOI 10.1038/s41416-025-03308-7↗
  4. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  5. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Last author DOI 10.1245/s10434-025-19046-2↗
  6. Anatomical evaluation of the perinephric vein as a surgical landmark in minimally invasive distal pancreatectomy for pancreatic cancer. Last author DOI 10.1007/s00464-025-12125-1↗
  7. Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. Last author DOI 10.1016/j.ejso.2025.109635↗
  8. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  9. Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal comparative study. Last author DOI 10.1093/bjsopen/zraf026↗
  10. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  11. Invited Editorial: Clinical Relevance of High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transection Margin in Patients with Pancreatic Ducta… Last author DOI 10.1245/s10434-025-17712-z↗
  12. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  13. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2024.10.001↗
  14. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Last author DOI 10.1093/bjs/znad417↗
  15. Unique Biology of Pancreatic Ductal Adenocarcinoma Accompanied by Rapidly Impaired Diabetes: A Favorable Long-Term Survival Following Curative Resection. Last author DOI 10.1245/s10434-023-14408-0↗
  16. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  17. Outcomes of pancreatic cancer with liver oligometastasis. Co-author DOI 10.1002/jhbp.1184↗
  18. Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal resectable pancreatic cancer. Last author DOI 10.1007/s00423-023-02942-0↗
  19. New approach of circumferential lymph node dissection around the superior mesenteric artery for pancreatic cancer during pancreaticoduodenectomy (with video). Last author DOI 10.1007/s00423-023-03159-x↗
  20. Radical antegrade modular pancreatosplenectomy enhances local control of the disease in patients with left-sided pancreatic cancer. Co-author DOI 10.1016/j.hpb.2022.08.004↗
  21. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with e… Last author DOI 10.1016/j.hpb.2022.09.012↗
  22. Intraoperative paraaortic lymph node sampling during resection for pancreatic cancer: evolving role in the modern chemotherapy era. Co-author DOI 10.1016/j.hpb.2023.05.366↗
  23. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  24. Outcomes of lung oligometastasis in pancreatic cancer. Co-author DOI 10.1093/jjco/hyad111↗
  25. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. Last author DOI 10.1245/s10434-023-13534-z↗
  26. Impact of sarcopenia on S1 adjuvant chemotherapy and prognosis in pancreatic cancer patients. Last author DOI 10.5582/bst.2023.01209↗
  27. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  28. Long-Term Outcome of Patients with Postoperative Refractory Diarrhea After Tailored Nerve Plexus Dissection Around the Major Visceral Arteries During Pancreato… Last author DOI 10.1007/s00268-022-06457-5↗
  29. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Co-author DOI 10.1016/j.pan.2022.04.003↗
  30. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  31. Diabetogenic liver metastasis from pancreatic cancer: a case report. Last author DOI 10.1186/s40792-022-01582-8↗
  32. Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. Co-author DOI 10.1245/s10434-021-10560-7↗
  33. ASO Author Reflections: Size Matters in Distal Pancreatic Cancer: Predictor for Failure of Upfront Resection for Radiologically Resectable Disease. Last author DOI 10.1245/s10434-021-10686-8↗
  34. Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with … Last author DOI 10.1245/s10434-022-11382-x↗
  35. Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Ret… Last author DOI 10.1245/s10434-022-11471-x↗
  36. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOL… Last author DOI 10.1245/s10434-022-11503-6↗
  37. ASO Author Reflections: Histology-Based Supervised Machine Learning Model Can Predict Recurrence Pattern of Pancreatic Cancer. Last author DOI 10.1245/s10434-022-11540-1↗
  38. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcit… Last author DOI 10.1245/s10434-022-11621-1↗
  39. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/invivo.13024↗
  40. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-021-01480-w↗
  41. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Last author DOI 10.1016/j.pan.2020.11.026↗
  42. Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and fluorescence imaging: the SLING trial. Last author DOI 10.1093/bjs/znaa111↗
  43. Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion. Co-author DOI 10.1002/bjs5.50268↗
  44. Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? Co-author DOI 10.1007/s00423-019-01846-2↗
  45. Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04203-2↗
  46. Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor locatio… Co-author DOI 10.1016/j.pan.2020.07.004↗
  47. Commentary: Complex venous resection and reconstruction for locally advanced pancreatic cancer: Our approach. First author DOI 10.1016/j.surg.2020.08.003↗
  48. Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety. Co-author DOI 10.1007/s11605-018-3995-3↗
  49. Techniques for splenic vein reconstruction after pancreaticoduodenectomy with portal vein resection for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.01.017↗
  50. Asymptomatic Pancreatic Cancer: Does Incidental Detection Impact Long-Term Outcomes? Co-author DOI 10.1007/s11605-017-3421-2↗

Closest collaborators

The 25 strongest of 101 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yosuke Inoue · 37 shared papers, 2017–2026 · strength 5.91
  2. Atsushi Oba · 30 shared papers, 2019–2026 · strength 5.16
  3. Hiromichi Ito · 31 shared papers, 2017–2025 · strength 5.02
  4. Yoshihiro Ono · 26 shared papers, 2019–2026 · strength 4.11
  5. Naoki Sasahira · 21 shared papers, 2020–2026 · strength 3.44
  6. Akio Saiura · 20 shared papers, 2019–2024 · strength 2.99
  7. Masato Ozaka · 16 shared papers, 2020–2026 · strength 2.69
  8. Takashi Sasaki · 16 shared papers, 2020–2026 · strength 2.61
  9. Tsuyoshi Takeda · 14 shared papers, 2020–2026 · strength 2.22
  10. Manabu Takamatsu · 12 shared papers, 2021–2026 · strength 2.01
  11. Takafumi Mie · 9 shared papers, 2020–2026 · strength 1.41
  12. Aya Maekawa · 7 shared papers, 2023–2026 · strength 1.28
  13. Takeshi Okamoto · 6 shared papers, 2021–2026 · strength 1.00
  14. Takaaki Furukawa · 6 shared papers, 2020–2026 · strength 0.92
  15. Yoshihiro Ono · 5 shared papers, 2022–2025 · strength 0.89
  16. Tomotaka Kato · 5 shared papers, 2022–2026 · strength 0.89
  17. Yuki Hirose · 5 shared papers, 2023–2025 · strength 0.87
  18. Akiyoshi Kasuga · 6 shared papers, 2020–2023 · strength 0.81
  19. Tatsunori Suzuki · 5 shared papers, 2022–2026 · strength 0.79
  20. Tsuyoshi Hamada · 5 shared papers, 2022–2026 · strength 0.79
  21. Kojiro Omiya · 4 shared papers, 2024–2025 · strength 0.74
  22. Yuta Ushida · 5 shared papers, 2021–2022 · strength 0.71
  23. Yosuke Inoue · 4 shared papers, 2023–2025 · strength 0.68
  24. Masato Matsuyama · 5 shared papers, 2020–2023 · strength 0.66
  25. Kiyoshi Hasegawa · 4 shared papers, 2022–2026 · strength 0.63

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.